This randomized, controlled, multi-center clinical trial aims to evaluate the efficacy and safety of prostatectomy for castration-Naive oligometastatic prostate cancer

Inclusion Criteria:

• Patients must be ≥ 40 and ≤75 years of age.
• All patients must have a histologically or cytologically diagnosis of prostate cancer.
• All patients must have been diagnosed oligometastatic prostate cancer which meet the following criteria. (1) ≤5 metastatic lesions are found by imaging examination (2)No visceral metastasis was found (3) The diameter of a single lesion ≤5cm or the surface area ≤250cm2.
• Patients previously treated with surgical castration or androgen deprivation therapy must maintain a testosterone level of <50ng/dl or <1.7nmol/L during treatment. Also the treatment duration should be less than 9 months. Patients were previously treated with at least 6 cycles of abiraterone.
• PSA<2ng/ml before enrollment.
• There was no PSA progression or radiographic progression during previous treatment.
• Primary lesion must be eligible for radical prostatectomy based on random radiographic assessment. ( Preoperative clinical staging \